Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities

Tan Li1, Guanyu Wang2

  • 1Department of Biology, South University of Science and Technology of China, 1088 Xueyuan Rd., Shenzhen 518055, China. li.t@sustc.edu.cn.

Insights

The PI3K/Akt/mTOR pathway is crucial for cell functions but often dysregulated in diseases like cancer. Computer-aided strategies can optimize targeted therapies to reduce side effects and improve patient outcomes.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Computational Biology

Background:

  • The Phosphatidylinositol 3-kinase/Akt/Mammalian target of rapamycin (PI3K/Akt/mTOR) pathway regulates vital cellular processes like metabolism, growth, and survival.
  • Dysregulation of this pathway is implicated in major diseases, including cancer, type 2 diabetes, and cardiovascular conditions.
  • While molecularly targeted therapies show promise, their efficacy is limited by pathway ubiquity and potential side effects.

Purpose of the Study:

  • To review factors modulating the PI3K/Akt/mTOR pathway.
  • To explore computer-aided strategies for optimizing targeted therapies against this pathway.
  • To discuss methods for reducing treatment toxicity and improving therapeutic outcomes.

Main Methods:

  • Literature review of factors influencing the PI3K/Akt/mTOR pathway (gene mutations, metabolites, toxicants, viruses).
  • Discussion of computational approaches for therapeutic strategy optimization.
  • Exploration of mathematical modeling, patient stratification, and molecular simulations (dynamics, docking).

Main Results:

  • Identified diverse modulators of the PI3K/Akt/mTOR pathway, highlighting its complex role in pathogenesis.
  • Proposed computer-aided targeting strategies to enhance precision and reduce toxicity of molecular therapies.
  • Highlighted potential for isoform-specific or mutation-selective drug discovery.

Conclusions:

  • Targeting the PI3K/Akt/mTOR pathway offers therapeutic potential for various diseases.
  • Computational methods are crucial for developing safer and more effective targeted treatments.
  • Further research can deepen understanding of pathway-related curability and toxicity.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K